1. New primary cutaneous malignant tumors.
2. Bleeding.
3. Cardiomyopathy.
4. Severe cutaneous reactions.
5. Serous retinopathy and retinal vein occlusion.
6. Hepatotoxicity.
7. Rhabdomyolysis.
FDA,2023.05